Quick Answer
CASTLE BIOSCIENCES INC reported Total Revenue of $344.23 million for fiscal year 2025.
CASTLE BIOSCIENCES INC — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $344.23M +3.7% |
$332.07M +51.1% |
$219.79M +60.4% |
$137.04M +45.7% |
$94.08M +50.2% |
$62.65M +20.8% |
| Revenue (ASC 606) | $344.23M +3.7% |
$332.07M +51.1% |
$219.79M +60.4% |
$137.04M +45.7% |
$94.08M +50.2% |
$62.65M +20.8% |
| Net Income | -$24.16M -232.4% |
$18.25M +131.7% |
-$57.47M +14.4% |
-$67.14M -114.6% |
-$31.29M -204.3% |
-$10.28M -294.9% |
| Diluted EPS | -$0.83 -233.9% |
$0.62 +129.0% |
-$2.14 +17.1% |
-$2.58 -108.1% |
-$1.24 -129.6% |
-$0.54 -157.1% |
| Total Assets | $578.56M +8.9% |
$531.24M +17.2% |
$453.34M +1.3% |
$447.33M -3.3% |
$462.57M +5.3% |
$439.33M +266.9% |
| Cash and Equivalents | $116.73M -2.5% |
$119.71M +21.1% |
$98.84M -19.6% |
$122.95M -62.7% |
$329.63M -19.6% |
$409.85M +314.6% |
| Long-Term Debt | $9.64M -1.1% |
$9.74M | $0.00 | — | — | $0.00 -100.0% |
| Stockholders Equity | $470.87M +3.3% |
$455.83M +16.5% |
$391.27M -2.0% |
$399.15M -3.1% |
$411.74M -1.0% |
$415.69M +388.4% |
| R&D Expense | $51.85M -0.4% |
$52.04M -2.9% |
$53.62M +19.4% |
$44.90M +51.5% |
$29.65M +123.6% |
$13.26M +79.5% |
| Operating Income | -$42.81M -593.8% |
$8.67M +112.8% |
-$67.98M +6.7% |
-$72.86M -81.8% |
-$40.08M -512.6% |
-$6.54M -189.3% |
| Gross Profit | — | — | — | — | — | $52.96M +18.9% |
| Shares Outstanding | 29.69M +4.2% |
28.48M +3.9% |
27.41M +3.2% |
26.55M +4.6% |
25.38M +2.3% |
24.81M +44.8% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $83.04M | -3.2% | -3.6% |
| Revenue (ASC 606) | September 30, 2025 | $83.04M | -3.2% | -3.6% |
| Net Income | September 30, 2025 | -$501.0K | -122.1% | -111.1% |
| Diluted EPS | September 30, 2025 | -$0.02 | -125.0% | -113.3% |
| Total Assets | September 30, 2025 | $562.79M | +9.4% | +3.3% |
| Cash and Equivalents | September 30, 2025 | $85.56M | -9.9% | +4.0% |
| Long-Term Debt | September 30, 2025 | $10.05M | +0.3% | +24.1% |
| Stockholders Equity | September 30, 2025 | $467.05M | +5.9% | +2.6% |
| R&D Expense | September 30, 2025 | $12.96M | +5.2% | +1.4% |
| Operating Income | September 30, 2025 | -$6.80M | -234.0% | -60.1% |
| Gross Profit | March 31, 2021 | $19.79M | +31.7% | +55.3% |
| Shares Outstanding | September 30, 2025 | 29.16M | +4.2% | +0.6% |
- CASTLE BIOSCIENCES INC reported Total Revenue of $344.23 million for fiscal year 2025.
- CASTLE BIOSCIENCES INC showed an increase of +3.7% in Total Revenue compared to the prior fiscal year.
- CASTLE BIOSCIENCES INC reported Revenue (ASC 606) of $344.23 million for fiscal year 2025.
- CASTLE BIOSCIENCES INC showed an increase of +3.7% in Revenue (ASC 606) compared to the prior fiscal year.
- CASTLE BIOSCIENCES INC reported Net Income of -$24.16 million for fiscal year 2025.
- CASTLE BIOSCIENCES INC showed a decrease of -232.4% in Net Income compared to the prior fiscal year.
- CASTLE BIOSCIENCES INC reported Diluted EPS of $0.83 per share (loss) for fiscal year 2025.
- CASTLE BIOSCIENCES INC showed a decrease of -233.9% in Diluted EPS compared to the prior fiscal year.
- CASTLE BIOSCIENCES INC reported Total Assets of $578.56 million for fiscal year 2025.
- CASTLE BIOSCIENCES INC showed an increase of +8.9% in Total Assets compared to the prior fiscal year.
- CASTLE BIOSCIENCES INC reported Cash and Equivalents of $116.73 million for fiscal year 2025.
- CASTLE BIOSCIENCES INC showed a decrease of -2.5% in Cash and Equivalents compared to the prior fiscal year.
- CASTLE BIOSCIENCES INC reported Long-Term Debt of $9.64 million for fiscal year 2025.
- CASTLE BIOSCIENCES INC showed a decrease of -1.1% in Long-Term Debt compared to the prior fiscal year.
- CASTLE BIOSCIENCES INC reported Stockholders Equity of $470.87 million for fiscal year 2025.
- CASTLE BIOSCIENCES INC showed an increase of +3.3% in Stockholders Equity compared to the prior fiscal year.
- CASTLE BIOSCIENCES INC reported R&D Expense of $51.85 million for fiscal year 2025.
- CASTLE BIOSCIENCES INC showed a decrease of -0.4% in R&D Expense compared to the prior fiscal year.
- CASTLE BIOSCIENCES INC reported Operating Income of -$42.81 million for fiscal year 2025.
- CASTLE BIOSCIENCES INC showed a decrease of -593.8% in Operating Income compared to the prior fiscal year.
- CASTLE BIOSCIENCES INC reported Gross Profit of $52.96 million for fiscal year 2020.
- CASTLE BIOSCIENCES INC showed an increase of +18.9% in Gross Profit compared to the prior fiscal year.
- CASTLE BIOSCIENCES INC reported Shares Outstanding of 29.69 million shares for fiscal year 2025.
- CASTLE BIOSCIENCES INC showed an increase of +4.2% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: